Tu Xu

4.2k total citations · 3 hit papers
29 papers, 2.4k citations indexed

About

Tu Xu is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Tu Xu has authored 29 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 10 papers in Hematology and 9 papers in Oncology. Recurrent topics in Tu Xu's work include Acute Myeloid Leukemia Research (9 papers), Neutropenia and Cancer Infections (6 papers) and Statistical Methods in Clinical Trials (6 papers). Tu Xu is often cited by papers focused on Acute Myeloid Leukemia Research (9 papers), Neutropenia and Cancer Infections (6 papers) and Statistical Methods in Clinical Trials (6 papers). Tu Xu collaborates with scholars based in United States, Australia and Germany. Tu Xu's co-authors include Brenda Chyla, Andrew H. Wei, Jalaja Potluri, Anthony Letai, Keith W. Pratz, Marina Konopleva, Brian A. Jonas, Daniel A. Pollyea, Courtney D. DiNardo and Martha Arellano and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Lancet Oncology.

In The Last Decade

Tu Xu

26 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia

2018 1.2k citations Courtney D. DiNardo, Keith W. Pratz et al. Blood profile →
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study

2018 498 citations Courtney D. DiNardo, Keith W. Pratz et al. The Lancet Oncology profile →
Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study

2019 456 citations Andrew H. Wei, Stephen A. Strickland et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tu Xu United States	12	1.9k	1.3k	496	481	438	29	2.4k
Guillermo Montalban‐Bravo United States	23	1.5k 0.8×	766 0.6×	519 1.0×	363 0.8×	361 0.8×	202	1.9k
Todd M. Cooper United States	24	1.2k 0.6×	667 0.5×	319 0.6×	724 1.5×	668 1.5×	116	2.0k
Christopher S. Hourigan United States	28	1.6k 0.8×	814 0.6×	376 0.8×	460 1.0×	444 1.0×	106	2.5k
Naval Daver United States	16	1.2k 0.6×	607 0.5×	372 0.8×	546 1.1×	348 0.8×	144	1.5k
Sanne Lugthart Netherlands	14	1.4k 0.7×	1.3k 1.0×	388 0.8×	325 0.7×	153 0.3×	26	2.0k
Jeffrey L. Wolf United States	27	1.9k 1.0×	1.5k 1.2×	255 0.5×	168 0.3×	1.2k 2.8×	116	2.6k
Vamsi Kota United States	19	887 0.5×	397 0.3×	397 0.8×	179 0.4×	408 0.9×	156	1.4k
Hareth Nahi Sweden	30	2.0k 1.1×	1.6k 1.2×	437 0.9×	129 0.3×	1.5k 3.4×	143	3.0k
Barbara Waßmann Germany	23	2.3k 1.2×	374 0.3×	1.1k 2.3×	1.2k 2.4×	534 1.2×	48	2.9k
Heather Oakervee United Kingdom	19	1.2k 0.6×	888 0.7×	184 0.4×	121 0.3×	639 1.5×	42	1.6k

Countries citing papers authored by Tu Xu

Since Specialization

Citations

This map shows the geographic impact of Tu Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tu Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tu Xu more than expected).

Fields of papers citing papers by Tu Xu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tu Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tu Xu. The network helps show where Tu Xu may publish in the future.

Co-authorship network of co-authors of Tu Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Tu Xu. A scholar is included among the top collaborators of Tu Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tu Xu. Tu Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wang, Chenkun, Junrui Di, Mercedeh Ghadessi, et al.. (2025). Insights on Clinical Development of Cell and Gene Therapy for Rare Diseases—by DahShu Innovative Design Scientific Working Group (IDSWG). Therapeutic Innovation & Regulatory Science. 59(6). 1336–1355.

Stahl, Mirjam, Jobst Roehmel, Monika Eichinger, et al.. (2024). Long-Term Impact of Lumacaftor/Ivacaftor Treatment on Cystic Fibrosis Disease Progression in Children 2–5 Years of Age Homozygous for F508del-CFTR : A Phase 2, Open-Label Clinical Trial. Annals of the American Thoracic Society. 21(11). 1550–1559. 5 indexed citations

Stahl, Mirjam, Jobst Roehmel, Monika Eichinger, et al.. (2023). Effects of Lumacaftor/Ivacaftor on Cystic Fibrosis Disease Progression in Children 2 through 5 Years of Age Homozygous for F508del-CFTR : A Phase 2 Placebo-controlled Clinical Trial. Annals of the American Thoracic Society. 20(8). 1144–1155. 13 indexed citations

Xu, Tu, et al.. (2023). Conduction and validation of a novel prognostic signature in cervical cancer based on the necroptosis characteristic genes via integrating of multiomics data. Computers in Biology and Medicine. 168. 107656–107656. 2 indexed citations

Wei, Andrew H., Stephen A. Strickland, Jing-Zhou Hou, et al.. (2019). Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study. Journal of Clinical Oncology. 37(15). 1277–1284. 456 indexed citations breakdown →

Grace, Rachael F., Paola Bianchi, Bertil Glader, et al.. (2019). An Ongoing Global, Longitudinal, Observational Study of Patients with Pyruvate Kinase Deficiency: The PEAK Registry. Blood. 134(Supplement_1). 2223–2223. 2 indexed citations

Wang, Xin, et al.. (2019). An efficient sample size adaptation strategy with adjustment of randomization ratio. Biometrical Journal. 61(3). 769–778.

Xu, Tu, et al.. (2018). Defining information fractions in group sequential clinical trials with multiple endpoints. Contemporary Clinical Trials Communications. 10. 77–79. 3 indexed citations

DiNardo, Courtney D., Keith W. Pratz, Anthony Letai, et al.. (2018). Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. The Lancet Oncology. 19(2). 216–228. 498 indexed citations breakdown →

10.

DiNardo, Courtney D., Keith W. Pratz, Vinod Pullarkat, et al.. (2018). Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 133(1). 7–17. 1175 indexed citations breakdown →

11.

Pollyea, Daniel A., Keith W. Pratz, Brian A. Jonas, et al.. (2018). Venetoclax in Combination with Hypomethylating Agents Induces Rapid, Deep, and Durable Responses in Patients with AML Ineligible for Intensive Therapy. Blood. 132(Supplement 1). 285–285. 32 indexed citations

12.

Stinchcombe, Thomas E., David Kozono, Joseph K. Salama, et al.. (2017). MA 17.07 Veliparib in Combination with Paclitaxel/Carboplatin (P/C)-Based Chemoradiotherapy (CRT) in Patients with Stage III NSCLC. Journal of Thoracic Oncology. 12(11). S1874–S1874. 1 indexed citations

13.

Roberts, Andrew W., Tu Xu, Jia Jia, et al.. (2017). Do Statins Enhance the Anti-Cancer Activity of Venetoclax?. Blood. 130. 1737–1737. 1 indexed citations

14.

Atrafi, Florence, Harry J.M. Groen, Lauren A. Byers, et al.. (2017). Phase 1/2 study of veliparib (V) combined with carboplatin (Cb) and etoposide (E) in patients (pts) with extensive-stage disease (ED) small cell lung cancer (SCLC) and other solid tumors: Phase 1 results.. Journal of Clinical Oncology. 35(15_suppl). 8530–8530. 4 indexed citations

15.

Xu, Tu, Yixin Fang, Alan Rong, & Junhui Wang. (2015). Flexible combination of multiple diagnostic biomarkers to improve diagnostic accuracy. BMC Medical Research Methodology. 15(1). 94–94. 34 indexed citations

16.

Xu, Tu. (2014). New Developments of Minimum Clinically Important Difference: Theory and Methodology. Figshare. 1 indexed citations

17.

Xu, Tu, Junhui Wang, & Yixin Fang. (2014). A model‐free estimation for the covariate‐adjusted Youden index and its associated cut‐point. Statistics in Medicine. 33(28). 4963–4974. 23 indexed citations

18.

Huang, Hsin‐Hsiung, Tu Xu, & Jie Yang. (2014). Comparing logistic regression, support vector machines, and permanental classification methods in predicting hypertension. BMC Proceedings. 8(S1). S96–S96. 25 indexed citations

19.

Xu, Tu & Junhui Wang. (2013). An efficient model-free estimation of multiclass conditional probability. Journal of Statistical Planning and Inference. 143(12). 2079–2088. 4 indexed citations

20.

Xu, Tu. (2012). The roles of ERK signal pathway and PDGF-B in the proliferation of aortic smooth muscle cells in rats.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact